Cancer immunology

Xilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at Frontiers in Cancer Immunotherapy Virtual Symposium

Retrieved on:

Wednesday, May 12, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Immune system, Clusters of differentiation, Cancer immunology, Oncology

XTX101 is specifically designed to target the anti-CTLA-4 effect geographically within the tumor and to minimize off-tumor peripheral effects.

Key Points:

XTX101 is specifically designed to target the anti-CTLA-4 effect geographically within the tumor and to minimize off-tumor peripheral effects.
We believe these data validate our approach, and we observed that XTX101 induces tumor-selective biological activity and robust tumor growth inhibition, with favorable tolerability, in preclinical studies.
The company\xe2\x80\x99s proprietary pipeline includes XTX202, a tumor-selective modified form of IL-2, and XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody (mAb), as well as tumor-selective IL-12 and IL-15 research programs.
For more information, please visit www.xiliotx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005177/en/\n'

ONCOTELIC THERAPEUTICS, INC. ANNOUNCED SYNERGY BETWEEN OT-101 AND IL-2 (PROLEUKIN) AT AACR-2021

Retrieved on:

Monday, April 19, 2021

Medical specialties, Branches of biology, Clinical medicine, Immunology, Oncology, Cancer immunology, Natural killer cell, T cells, Cytokine, Transforming growth factor beta

The expression of TGF-\xce\x92 correlates with malignancy of various cancers and involves immunosuppression and angiogenesis of a tumor.

Key Points:

The expression of TGF-\xce\x92 correlates with malignancy of various cancers and involves immunosuppression and angiogenesis of a tumor.
IL-2 is a major cytokine to proliferate T cells and NK cells which are major players of cancer immunity.
Combination treatment of TGF-\xce\xb2 inhibitor and IL-2 would have an anti-tumor effect by immune cells through diminishing immunosuppression by TGF-\xce\xb2 and enforcement of immune cells by IL-2.
It is shown that Trabedersen is well tolerable in cancer patients and effective reagent to treat pancreatic cancer, melanoma, and glioblastoma.

Amphivena Presents Translational Data Highlighting the Cytokine Profile for its Lead Clinical Candidate, AMV564 at the AACR 2021 Virtual Annual Meeting

Retrieved on:

Monday, April 12, 2021

Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Clinical medicine, Medicine, Medical specialties, Cancer immunotherapy, Oncology, MDSC, Cancer immunology, Immunotherapy, Myeloid-derived suppressor cell, AMV564, Amphivena Therapeutics, Inc.

b'Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immuno-therapeutics that restore anti-cancer immunity, today presents translational data for the Company\xe2\x80\x99s lead clinical candidate from a Phase 1 study in patients with advanced solid tumors.

Key Points:

b'Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immuno-therapeutics that restore anti-cancer immunity, today presents translational data for the Company\xe2\x80\x99s lead clinical candidate from a Phase 1 study in patients with advanced solid tumors.
AMV564 relieves immune suppression via MDSC depletion which results in the expansion of anti-tumor T-cells, while attenuating the biological responses that contribute to cytokine release syndrome.
The company\xe2\x80\x99s lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy.
AMV564-induced immune restoration is optimized by targeting the lymphoid tissues through subcutaneous delivery where immunoregulation occurs.

Immune-Onc Therapeutics Announces First Public Presentation of Data for its Myeloid Checkpoint Inhibitor, IO-202, in Solid Tumors at AACR21

Retrieved on:

Saturday, April 10, 2021

Immune-Onc Therapeutics, Inc. (Immune-Onc), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced today the first public presentation of preclinical data for its first-in-class myeloid checkpoint inhibitor, IO-202, an LILRB4 antagonist antibody, in solid tumors.

Key Points:

Immune-Onc Therapeutics, Inc. (Immune-Onc), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced today the first public presentation of preclinical data for its first-in-class myeloid checkpoint inhibitor, IO-202, an LILRB4 antagonist antibody, in solid tumors.
Myeloid cells are abundant and often immune suppressive in the solid tumor microenvironment (TME).
LILRB4 (also known as ILT3) is expressed on monocytic myeloid cells, offering rationale for investigating the potential of IO-202 in solid tumors.
IO-202 may be combined with anti-PD-(L)1, other immunotherapies, and/or immunogenic chemotherapy in future investigations of novel treatment approaches for solid tumors.

ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on:

Friday, April 9, 2021

Clusters of differentiation, Clinical medicine, Medical specialties, Medicine, Cancer immunotherapy, Immune system, PD-L1, PD-1 and PD-L1 inhibitors, Programmed cell death protein 1, L1, Checkpoint inhibitor, Cancer immunology

MOUNTAIN VIEW, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Companys orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the American Association for Cancer Research (AACR).

Key Points:

MOUNTAIN VIEW, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Companys orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the American Association for Cancer Research (AACR).
The poster presentation, which showcases CCX559s ability to induce anti-tumor immunity, will go live on Saturday, April 10 at 8:30 a.m.
PD-L1/PD-1 interaction is one of the major checkpoints that limit effector T cell function against cancer cells.
The study featured in the AACR poster presentation demonstrated that CCX559 potentially employs distinct mechanisms to inhibit PD-L1 compared to the anti-human PD-L1 antibodies.

Istari Oncology Announces Publication of Data Showing the Investigational Immunotherapy PVSRIPO Leads to Robust, Functional T Cells—Critical for Antitumor Immunity

Retrieved on:

Thursday, March 25, 2021

Biotechnology, Health, Science, Research, Oncology, Medical specialties, Branches of biology, Clinical medicine, Immunology, Immune system, Antiviral drugs, Cytokines, Receptors, Cancer immunology, Interferon, Immunotherapy, Vaccine, PVSRIPO, Istari Oncology

PVSRIPO is genetically engineered to elicit potent, sustained innate antiviral inflammatory patterns, which yield vigorous CD8+ T cell responses in the TME, without significant toxicity.

Key Points:

PVSRIPO is genetically engineered to elicit potent, sustained innate antiviral inflammatory patterns, which yield vigorous CD8+ T cell responses in the TME, without significant toxicity.
PVSRIPOs activation of a specific pattern recognition receptor, MDA5, leads to the optimal cytokine signaturethe sustained, type-I/III IFN-dominant response that is required to achieve robust anticancer immunity.
For more information about Istari Oncology and their ongoing clinical trials and research in PVSRIPO, visit www.istarioncology.com .
PVSRIPO is an investigational immunotherapy based on the live attenuated Sabin type 1 poliovirus vaccine that has been genetically modified for safety.

ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant Tumors

Retrieved on:

Monday, March 22, 2021

Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Life sciences, Health sciences, Clinical medicine, Tumor, PD-L1, Biological engineering, Biotechnology, Oncology, Tumor microenvironment, Immunotherapy, Cancer immunology, Tumor-associated macrophage

Human solid tumors are made of multiple clones of tumor cells, some of which harbor genomic alterations that make them invisible to T cells.

Key Points:

Human solid tumors are made of multiple clones of tumor cells, some of which harbor genomic alterations that make them invisible to T cells.
For these patients, maximum activation of T cells with immunotherapy is unlikely to lead to durable tumor control or a cure.
The study shows that when subpopulations of tumors cells escape T cell detection or killing, they upregulate PD-L1 in the process because of interferon in the tumor microenvironment.
ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

Checkpoint Inhibitor Response Prediction Milestone Achieved in KIYATEC Study Detecting Ex Vivo Cancer Patient-Specific Immune Response

Retrieved on:

Thursday, March 11, 2021

Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Medical specialties, Medicine, Immune system, Cancer immunotherapy, Clusters of differentiation, Virotherapy, PD-L1, Immunotherapy, Checkpoint inhibitor, Oncology, Cancer immunology

today announced that research published in the March 2021 Cancer Immunology, Immunotherapy journal solidifies the foundation to characterize predictive accuracy in immuno-oncology.

Key Points:

today announced that research published in the March 2021 Cancer Immunology, Immunotherapy journal solidifies the foundation to characterize predictive accuracy in immuno-oncology.
Immune checkpoint inhibitors that target programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) have only shown modest activity as monotherapies for the treatment of ovarian cancer.
Approval for a patients use of these immunotherapies is based on the current paradigm of cancer drug selection, spanning genetic sequencing, gene expression and biomarkers.
The importance of checkpoint inhibitors meeting key clinical endpoints has recently been brought into focus in more than one cancer indication.

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of Cancer

Retrieved on:

Tuesday, January 26, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Clinical medicine, Medicine, Oncology, Immunology, Immune system, Cancer immunotherapy, Immune checkpoint, Immunotherapy, CD137, Cancer immunology, CD28 family receptor

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical studies of Bicycles novel, fully synthetic Bicycle systemic immune cell agonists and tumor-targeted immune cell agonists (TICAs) was published in the Journal for ImmunoTherapy of Cancer (JITC).

Key Points:

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical studies of Bicycles novel, fully synthetic Bicycle systemic immune cell agonists and tumor-targeted immune cell agonists (TICAs) was published in the Journal for ImmunoTherapy of Cancer (JITC).
The article, titled Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist is available online via this link .
In contrast to immune checkpoint inhibitors, the use of antibodies as agonists of immune costimulatory receptors as cancer therapeutics has largely failed.
The article outlines the work Bicycle is undertaking to unlock a new method of cancer immunotherapy via small molecule agonism of TNF superfamily receptors.

Amphivena Therapeutics Announces First Patient Dosed in the Phase 1 Dose Expansion of AMV564

Retrieved on:

Wednesday, December 16, 2020

Medical specialties, Cancer immunology, Oncology, Response Evaluation Criteria in Solid Tumors, Medicine, Clinical medicine

The dose escalation phase of the first-in-human, multicenter, open-label study of AMV564 in solid tumors was initiated in October 2019 and established the safety, PK profile and clinical activity of AMV564 including a confirmed RECIST complete response.

Key Points:

The dose escalation phase of the first-in-human, multicenter, open-label study of AMV564 in solid tumors was initiated in October 2019 and established the safety, PK profile and clinical activity of AMV564 including a confirmed RECIST complete response.
The dose expansion study will explore AMV564 as a monotherapy in tumor-specific cohorts selected to enrich for patients with actionable antigens.
The primary objectives of the study are to further characterize the safety and tolerability and to evaluate preliminary efficacy of AMV564 monotherapy administered subcutaneously.
AMV564 relieves immune suppression via targeted depletion of immunosuppressive MDSC and drives T cell activation and polarization to restore anti-cancer immunity.